Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.
CNN — The biotechnology company Novavax now plans to apply for emergency use authorization of its Covid-19 vaccine in the US in the third quarter of this year, CEO Stanley Erck told CNN in a phone ...
NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...
It should be a great time to be the vaccine maker Novavax. As the Trump administration and its public health appointees have turned firmly against messenger RNA-based vaccines, Novavax still sells the ...